精神分裂症患者启动GLP-1受体激动剂前后的代谢生物标志物水平:中断时间序列分析
基于丹麦全国登记数据,识别1996至2023年间启动GLP-1RA治疗的精神分裂症患者3042例,采用中断时间序列分析评估治疗启动后HbA1c、LDL和甘油三酯水平的变化。因糖尿病启动GLP-1RA后上述指标分别降低11.4%、6.2%和14.8%,因超重启动后分别降低3.4%、4.9%和12.7%,所有变化均具有统计学显著性(p < 0.001)。
要点
- 真实世界中精神分裂症患者启动GLP-1RA后HbA1c、LDL和甘油三酯均显著下降。
- 因糖尿病启动者HbA1c降幅11.4%,因超重启动者降幅3.4%。
- 代谢获益与随机对照试验结果一致,支持真实临床环境中的使用。
核心结论
- 精神分裂症患者启动GLP-1RA治疗后,HbA1c、LDL和甘油三酯水平出现具有临床意义的降低。
- 随机临床试验中观察到的GLP-1RA代谢获益可延伸至真实世界临床环境。
研究设计与样本
- 基于丹麦全国登记数据,识别1996至2023年间精神分裂症患者中启动GLP-1RA治疗者。
- 采用中断时间序列分析量化治疗启动后HbA1c、LDL和甘油三酯水平的变化。
主要发现
- 共识别3042例启动GLP-1RA治疗的精神分裂症患者。
- 因糖尿病启动GLP-1RA后,HbA1c、LDL和甘油三酯分别降低11.4%、6.2%和14.8%。
- 因超重启动GLP-1RA后,HbA1c、LDL和甘油三酯分别降低3.4%、4.9%和12.7%。
- 所有水平变化均具有统计学显著性(p < 0.001)。
关键数值与推荐
- 因糖尿病启动GLP-1RA:HbA1c降低11.4%,LDL降低6.2%,甘油三酯降低14.8%(p < 0.001)。
- 因超重启动GLP-1RA:HbA1c降低3.4%,LDL降低4.9%,甘油三酯降低12.7%(p < 0.001)。
临床怎么用
- 在精神分裂症患者中启动GLP-1RA治疗时,可预期HbA1c、LDL和甘油三酯水平获得临床意义的改善。
- 真实世界证据支持将随机对照试验中GLP-1RA的代谢获益应用于精神分裂症患者的常规临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised controlled trials have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduces body weight, waist circumference and haemoglobin A1c (HbA1c) levels in patients with schizophrenia. However, because of participant selection in clinical trials, it remains unclear whether the beneficial metabolic effects of GLP-1RAs for patients with schizophrenia extend to real-world clinical settings. AIMS: We investigated whether GLP-1RA treatment initiation was associated with reductions in HbA1c, low-density lipoprotein (LDL) and triglyceride levels (the latter two as proxies for weight loss) in individuals with schizophrenia. METHOD: We used the Danish nationwide registers to identify individuals with schizophrenia between 1996 and 2023. Among those, we identified individuals initiating GLP-1RA treatment. The main outcomes were changes in HbA1c, LDL and triglyceride levels following initiation of GLP-1RA treatment. Changes in HbA1c, LDL and triglyceride levels were visualised graphically and quantified with interrupted time-series analyses. RESULTS: We identified 3042 individuals with schizophrenia who initiated a GLP-1RA. Initiation of GLP-1RA treatment for diabetes was followed by reductions in HbA1c, LDL and triglyceride levels of 11.4, 6.2 and 14.8%, respectively. Initiation of GLP-1RA treatment for overweight was followed by reductions in HbA1c, LDL and triglyceride levels of 3.4, 4.9 and 12.7%, respectively. All level changes were statistically significant (p < 0.001). CONCLUSIONS: Initiation of GLP-1RA treatment was followed by clinically meaningful reductions in HbA1c, LDL and triglyceride levels among individuals with schizophrenia. These findings suggest that the metabolic benefits of GLP-1RA treatment found in randomised clinical trials in schizophrenia extend to real-world clinical settings.
引用
- Mikkelsen NB, Ørberg A, Østergaard SD, et al. Metabolic biomarker levels before and after initiation of GLP-1 receptor agonist treatment among individuals with schizophrenia: interrupted time-series analysis. Br J Psychiatry. 2026. PMID: 42922018. doi:10.1192/bjp.2026.10863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。